HOWL – werewolf therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.
Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: MPM BioVentures 2014, L.P.
Form 4 Werewolf Therapeutics, For: Jan 13 Filed by: EVNIN LUKE
Form 4 Werewolf Therapeutics, For: Jan 08 Filed by: EVNIN LUKE
Form 4 Werewolf Therapeutics, For: Jan 05 Filed by: EVNIN LUKE
Form 144 Werewolf Therapeutics, Filed by: MPM ASSET MANAGEMENT LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.